NASDAQ : SXTP

60 Degrees Pharmaceuticals, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 0.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.31M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Details

Name60 Degrees Pharmaceuticals, Inc.
SectorHealthcare
IndustryBiotechnology
Employees3
Founded2010
Ipo Date2023-07-12
CeoGeoffrey Dow
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price5.30
IsinUS83006G5009
Cusip83006G500
Cik1946563
Sic2834
Stock TypeCommon Stock
Share ClassClass A Shares

Key executives

NameTitle
Dr. Geoffrey Stuart Dow Ph.D.Chairman, Chief Executive Officer and President
Tyrone MillerChief Financial Officer
Kristen LandonChief Commercial Officer
Dr. Bryan SmithChief Medical Officer

Contact

Address1025 Connecticut Avenue NW, Suite 1000, Washington, District of Columbia 20036, United States
Phone202 327 5422
Websitehttps://www.60degreespharma.com